{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:18:28Z","timestamp":1761718708615,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/25"],"award-info":[{"award-number":["14\/25"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40273-018-0680-z","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T03:41:46Z","timestamp":1530070906000},"page":"7-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ibrutinib for Treating Waldenstr\u00f6m\u2019s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":false,"given":"Paul","family":"Tappenden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen","family":"Thokala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"680_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 ."},{"key":"680_CR2","unstructured":"Tappenden P, Carroll C, Stevens J, Simpson E, Thokala P, Sanderson J, et al. Ibrutinib for treating Waldenstr\u00f6m\u2019s macroglobulinaemia: evidence review group report submitted to the National Institute for Health and Care Excellence. Sheffield; University of Sheffield; 2016. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/committee-papers ."},{"key":"680_CR3","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating Waldenstrom\u2019s macroglobulinaemia: final appraisal determination. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/final-appraisal-determination-document ."},{"key":"680_CR4","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating Waldenstrom\u2019s macroglobulinaemia: technology appraisal guidance 491. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta491 ."},{"key":"680_CR5","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating Waldenstrom\u2019s macroglobulinaemia. London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta491\/history ."},{"key":"680_CR6","unstructured":"European Medicines Agency. Imbruvica\u2014Committee for Medicinal Products for Human Use (CHMP) assessment report variation. London: EMA; 2015. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003791\/human_med_001801.jsp&mid=WC0b01ac058001d124 ."},{"issue":"18","key":"680_CR7","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia. Blood. 2009;113(18):4163\u201370.","journal-title":"Blood"},{"key":"680_CR8","unstructured":"Janssen Ltd. Ibrutinib for treating Waldenstr\u00f6m\u2019s macroglobulinaemia. Company\u2019s evidence submission to the National Institute for Health and Care Excellence. High Wycombe, Buckinghamshire: Janssen; 2016. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/committee-papers ."},{"issue":"Suppl. 6","key":"680_CR9","doi-asserted-by":"crossref","first-page":"vi155","DOI":"10.1093\/annonc\/mdt298","volume":"2013","author":"C Buske","year":"2013","unstructured":"Buske C, Leblond V, Dimopoulos M, Kimby E, Jager U, Dreyling M, et al. Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;2013(Suppl. 6):vi155\u20139.","journal-title":"Ann Oncol"},{"issue":"3","key":"680_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.12760","volume":"165","author":"R Owen","year":"2014","unstructured":"Owen R, Pratt G, Auer R, Flatley R, Kyriakou C, Lunn M, et al. Guidelines on the diagnosis and management of Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2014;165(3):316\u201333.","journal-title":"Br J Haematol"},{"key":"680_CR11","unstructured":"National Institute for Health and Care Excellence. Ibrutinib for treating Waldenstrom\u2019s macroglobulinaemia: Final scope. London: NICE; 2016. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/committee-papers ."},{"key":"680_CR12","unstructured":"Janssen Ltd. Ibrutinib for treating Waldenstr\u00f6m\u2019s macroglobulinaemia. Company\u2019s response to the ERG\u2019s clarification questions. High Wycombe, Buckinghamshire: Janssen; 2016. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/committee-papers ."},{"issue":"15","key":"680_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372(15):1430\u201340.","journal-title":"N Engl J Med"},{"key":"680_CR14","unstructured":"Pharmacyclics Inc. Clinical Study Report: Phase 2 study of Bruton\u2019s tyrosine kinase inhibitor (BTK), ibrutinib (PCI-32765). In: Waldenstr\u00f6m\u2019s macroglobulinemia. PCYC-118E. California; 2014."},{"issue":"23","key":"680_CR15","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.V126.23.2096.2096","volume":"126","author":"C Buske","year":"2015","unstructured":"Buske C, Sadullah S, Kastritis E, Benevolo G, Garcia-Sanz R, Bolkun Lukasz, et al. Generation of a large observational Pan-European data platform for treatment and outcome patterns in patients with Waldenstrom\u2019s macroglobulinemia. Blood. 2015;126(23):2096.","journal-title":"Blood"},{"issue":"3","key":"680_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"25","key":"680_CR17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"issue":"6","key":"680_CR18","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(6):2497\u2013506.","journal-title":"Blood"},{"issue":"1","key":"680_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"680_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood"},{"issue":"2","key":"680_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171\u20136.","journal-title":"Br J Haematol"},{"key":"680_CR22","unstructured":"Office for National Statistics. National Life Tables. London: ONS; 2015. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/2015-09-23 ."},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O\u2019Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"680_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"K Tolley","year":"2013","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749\u201359.","journal-title":"Eur J Health Econ"},{"key":"680_CR25","unstructured":"BMJ Group. RCPCH Publications Ltd and The Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF); 2016. https:\/\/bnf.nice.org.uk\/ ."},{"key":"680_CR26","unstructured":"Department of Health. NHS Reference Costs 2014\/15. London: DH; 2015. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/ ."},{"issue":"10","key":"680_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269216315595203","volume":"29","author":"J Round","year":"2015","unstructured":"Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: A modelling study. Palliat Med. 2015;29(10):899\u2013907.","journal-title":"Palliat Med"},{"key":"680_CR28","unstructured":"Tappenden P, Thokala P, Sanderson J. Ibrutinib for treating Waldenstr\u00f6m\u2019s macroglobulinaemia: ERG commentary on the company\u2019s response to the ACD. Sheffield: University of Sheffield; 2016. https:\/\/www.nice.org.uk\/guidance\/ta491\/documents\/committee-papers-4 ."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0680-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T10:41:31Z","timestamp":1604486491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0680-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0680-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"27 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project No. 15\/148\/03) [see the HTA programme website for further project information;]. This summary of the ERG report was compiled after NICE issued the FAD. All authors have commented on the submitted manuscript and have given their approval for the final version to be published. The views expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rebecca Auer acted as an advisor for Janssen for their submission to NICE and was paid a small advisory fee for this role. Since the completion of this appraisal, she has received a grant for a clinical trial that is anticipated to begin in November 2018. Paul Tappenden, Christopher Carroll, John Stevens, Emma Simpson, Praveen Thokala, Ruth Wong and Josh Wright declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}